No abstract text available.
Hospital Admitted Care Activity. NHS digital. https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-care-activity
Herschorn S, Gajewski J, Ethans K, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185:2229-2235.
Scaglione F. Conversion Ratio Between Botox, Dysport, and Xeomin in Clinical Practice. Toxins. Vol 8, 2016.
Botox 200 units powder for solution for injection. Allergan Ltd. https://www.medicines.org.uk/emc/product/436/smpc#UNDESIRABLE_EFFECTS
Dysport 300 units powder for solution for injection. Ipsen Ltd. https://www.medicines.org.uk/emc/product/964
Xeomin 100 units powder for solution for injection. Merz Pharma UK Ltd. https://www.medicines.org.uk/emc/product/6202/smpc
Naumann N, Jankovic J 7. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004;20:281-290.
Patki PS, Hamid R, Arumugam K, SHAH PJR, CRAGGS M 1, June. Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. BJU Int. 2006;98:77-82.
Cheng T, Shuang WB, Jia DD, et al. 7. Efficacy and safety of onabotulinumtoxin A in patients with neurogenic detrusor overactivity: a systematic review and meta-analysis of randomized controlled trials. PLOS One. 2016;11.
Gong Q, Xu Y, Xu J, Ding X, Guo C. Meta-analysis of randomized controlled trials using botulinum toxin A at different dosages for urinary incontinence in patients with overactive bladder. Front Pharmacol. 2019;10:1618.
Coban A, Matur Z, Hanagasi HA, Parman Y 3, May. Iatrogenic botulism after botilinum toxin type A injections. Clin Neuropharmacol. 2010;22:158-160.
Nuanthaisong U, Abraham N, Goldman HB 5. Incidence of adverse events after high doses of onabotulinumtoxinA for multiple indications. Urology. 2014;84:1044-1048.
British National Formulary. National Institute for Health and Care Excellence [online]. 2020. https://bnf.nice.org.uk/drug/botulinum-toxin-type-a.html#indicationsAndDoses
Al-Ghamdi AS, Alghanemy N, Joharji H, Al-Qahtani D, Alghamdi H. Botulinum toxin: non-cosmetic and off label dermatological uses. J Dermatol Dermatologic Surg. 2015;19(1):1-8.
Simmons D, Gamble GC, Foote S. The New Zealand diabetes passport study: a randomized controlled trial of the impact of a diabetes passport on risk factors for diabetes-related complications. Diabet Med. 2004;21(3):214-217.
National Institute for Health and Care Excellence. Anticoagulation-oral: scenario: Warfarin [online]. 2020. https://cks.nice.org.uk/topics/anticoagulation-oral/management/warfarin/
